Pharmaceutical Industry
Filter News
Found 26,692 articles
-
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
10/21/2020
Samsung Biologics maintained steady financial results for its fiscal 2020 third quarter ending September 30, demonstrating confident execution of its ongoing business operations.
-
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
10/21/2020
50% (2/4) complete response (CR)rate at three months in the Dose Level 3 (DL3)cohort; both respondersremain in CR
-
CareDx Showcases Leading Transplant Data at ASN 2020General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meeting
10/21/2020
CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced a leading presence with AlloSure education at the American Society of Nephrology annual conference from October 22 – 25, 2020.
-
Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx
10/21/2020
Tetra will leverage its recent Dronabinol data pack acquisition to rapidly file its second New Drug Submission application to commercialize another THC-based prescription drug
-
Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans
10/21/2020
Additional Analysis Shows Potential of Biktarvy to Be an Important Treatment Option for People Living With HIV Who are Virologically Suppressed and Have End Stage Renal Disease Requiring Hemodialysis
-
IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol
10/21/2020
IntelGenx Corp. announced that it has entered into an amended and restated license agreement granting Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, additional exclusive worldwide rights, including the right to manufacture, IntelGenx’s Adversa® mucoadhesive delivery technology.
-
Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting
10/21/2020
n, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced that it will present two poster presentations covering AT-007 in Galactosemia at the upcoming American Society of Human Genetics 2020 Annual Meeting.
-
ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020
10/21/2020
ADMA Biologics, Inc. announced an exclusive educational event at IDWeek 2020 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Lisa Forbes Satter from Baylor College of Medicine and Texas Children’s Hospital, as well as new data on Streptococcus pneumonia in an on-demand poster session.
-
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020
10/21/2020
Data from More Than 50 Clinical and Epidemiological Abstracts Across Vaccines, HIV, Antibiotics and Antimicrobials Show the Breadth of the Company’s Commitment to Addressing the Threat of Infectious Diseases
-
Ionis to hold third quarter 2020 financial results webcast
10/21/2020
Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Wednesday, November 4th at 11:30 a.m. Eastern Time to discuss its third quarter 2020 financial results and report on pipeline and business progress.
-
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
10/21/2020
PTG-300 was previously granted orphan drug designation by the U.S. Food and Drug Administration
-
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
10/21/2020
NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma
-
Syneos Health® Launches Kinetic™ Omnichannel Capability to Accelerate Modern Customer EngagementIntegrating Intelligence Across Channels, Technologies and Content Achieves Greater Precision, Efficiency and Effectiveness
10/21/2020
Syneos Health, the only fully integrated biopharmaceutical solutions organization, introduced Kinetic, a modern customer engagement capability that makes fully integrated omnichannel solutions accessible to biopharmaceutical organizations.
-
Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease
10/21/2020
$1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
-
MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair
10/21/2020
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced the appointment of Ms. Carolyn Beaver to its Board of Directors and as Chair of its Audit Committee.
-
Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China
10/21/2020
Ascentage Pharma announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Guangzhou Healthquest Pharma Co., Ltd, a wholly-owned subsidiary of the company, priority review to its New Drug Application for Olverembatinib.
-
TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer
10/21/2020
TLC, a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the appointment of Thomas H. Bliss, Jr., MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development.
-
Nomination committee in Oncopeptides established
10/21/2020
Oncopeptides AB, announced that the composition of the Nomination Committee for the Annual General Meeting 2021 has been established.
-
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
-
Shares of Aptinyx skyrocketed more than 75% after the company reported its mid-stage experimental treatment for post-traumatic stress disorder demonstrated clinically meaningful and statistically significant results that will set up a pivotal study next year.